| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | 1 | — | — | — | — |
| Sell | 3 | — | — | 3 | 1 | — | 3 | — | — | 2 | 1 | — |
| total | individual payouts | |
|---|---|---|
| 2024 | ‡‡‡ |
|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 91.83 | 65.59 | 48.72 | 28.04 |
| Receivables | 126.00 | 107.05 | 85.26 | 70.50 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 223.93 | 177.98 | 137.28 | 101.07 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 4.43 | 3.69 | 3.36 | 1.25 |
| ST’ Debt | — | 45.86 | — | — |
| Other | 39.40 | 4.56 | — | — |
| 171.15 | 148.96 | 78.39 | 62.35 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 34.32 | 36.88 | — | — |
—
|
| ’25 | 56.44 | 58.04 | 52.03 | 66.77 |
233.27
|
| ’24 | 67.61 | 69.64 | 67.06 | 74.00 |
278.30
|
| ’23 | 64.33 | 76.70 | 79.01 | 89.17 |
309.20
|
| ’22 | 67.93 | 75.41 | 72.71 | 82.50 |
298.54
|
| ’21 | 53.23 | 58.85 | 64.98 | 90.05 |
267.12
|
| ’20 | 45.51 | 28.22 | 46.08 | 67.08 |
186.89
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (5.64) | (8.60) | — | — |
—
|
| ’25 | (6.71) | 1.23 | 1.76 | 13.01 |
9.29
|
| ’24 | (17.62) | 4.43 | 1.39 | 2.98 |
(8.82)
|
| ’23 | (10.06) | 5.75 | 1.19 | 2.93 |
(0.18)
|
| ’22 | (19.69) | (6.68) | (14.43) | (13.10) |
(53.90)
|
| ’21 | (12.53) | (14.98) | (10.46) | (0.55) |
(38.52)
|
| ’20 | (3.41) | (4.24) | (5.57) | 5.62 |
(7.60)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (7.95) | (10.70) | — | — |
—
|
| ’25 | (10.81) | (3.43) | (2.70) | 10.45 |
(6.49)
|
| ’24 | (22.36) | (0.43) | (3.87) | (1.46) |
(28.12)
|
| ’23 | (12.87) | 3.00 | (1.95) | (0.76) |
(12.58)
|
| ’22 | (22.45) | (10.95) | (17.74) | (16.25) |
(67.39)
|
| ’21 | (15.86) | (17.93) | (13.33) | (3.97) |
(51.09)
|
| ’20 | (4.84) | (6.19) | (8.44) | 1.76 |
(17.71)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.80) | (2.58) | — | — |
—
|
| ’25 | (2.60) | (1.80) | (13.60) | (1.50) |
(19.50)
|
| ’24 | (5.60) | (0.90) | (29.00) | (3.10) |
(39.10)
|
| ’23 | 4.00 | (6.70) | (6.30) | (25.60) |
(36.90)
|
| ’22 | 8.90 | (37.50) | 1.90 | (113.20) |
(139.20)
|
| ’21 | (8.50) | (14.30) | (13.50) | (3.50) |
(39.90)
|
| ’20 | (5.10) | (7.30) | (5.60) | (2.40) |
(20.40)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 35.00 | 25.70 | 28.90 | 8.52 | — | — | — |
Low Price
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 734.10 | 195.70 | 205.20 | 40.45 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 501 | 434 | 454 | 275 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.60 | 0.71 | 0.61 | 0.85 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 298.54 | 309.20 | 278.30 | 233.27 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 37.73% | 42.17% | 43.44% | 44.85% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (466.71) | (134.70) | (189.30) | (103.49) | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (156.33%) | (43.56%) | (68.02%) | (44.36%) | ‡‡‡ | ‡‡‡ | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (465.26) | (134.70) | (189.30) | (103.49) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 498.62 | 101.68 | 161.10 | 87.77 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 89.33 | 84.74 | 57.55 | 43.92 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (139.20) | (36.90) | (39.10) | (19.50) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (16.13) | (0.05) | (1.82) | 1.75 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (4.04) | (3.40) | (3.99) | (2.97) | ‡‡‡ | ‡‡‡ | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (20.17) | (3.45) | (5.81) | (1.22) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 63.32 | 36.94 | 14.47 | (1.23) | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.34 | 3.65 | 4.84 | 5.31 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Shares
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.60 | 1.05 | 0.64 | 0.26 | ‡‡‡ | ‡‡‡ | — |
PS Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.85 | 2.41 | 2.56 | 0.00 | ‡‡‡ | ‡‡‡ | — |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.97 | 1.68 | 1.18 | 1.15 | ‡‡‡‡ | ‡‡‡‡ | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (4.29) | (40.81) | (11.57) | (40.10) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (53.90) | (0.18) | (8.82) | 9.29 | ‡‡‡ | ‡‡‡ | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.49) | (12.39) | (19.30) | (15.78) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (67.39) | (12.58) | (28.12) | (6.49) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.10 | 52.78 | 29.03 | 58.89 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 231.05 | 257.50 | 213.59 | 208.92 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 109.06 | 165.67 | 148.00 | 160.20 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 211.61 | 134.80 | 69.99 | (6.51) | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (47.60%) | (21.29%) | (39.16%) | (30.51%) | — | — | — |
ROA
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (89.22%) | (28.22%) | (56.05%) | (41.40%) | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (103.13%) | (77.77%) | (184.88%) | (326.02%) | — | — | — |
ROE
|
Cardlytics (CDLX), once a darling of the digital ad boom, has cratered over 98% from 2021 peaks after a post-IPO surge, now trading at distressed multiples amid stalled growth and gaping losses exceeding $1.3 billion cumulatively. Revenue, which compounded at 28% through 2023 peaks driven by bank partnerships like Bank of America and Chase, reversed with a 10% drop in 2024 and analysts forecasting 17% further declines in 2025—correlating with workforce cuts, banking turmoil, and ad-targeting headwinds from privacy regs.
Persistent red ink plagues profitability, with negative ROE/IC below -20%, ballooning shares from dilutive raises, and free cash flow deficits topping $300 million, fueling a balance sheet on the brink: equity eroded 90% to $70 million, net debt at $148 million, and liquidity squeezed. Insider action screams caution—zero buys amid 800k+ shares sold, including a massive 400k dump by a top owner—while volatile stock history and cheap EV/Sales (0.22x forward) mask leverage risks in a high-rate world.
Analysts peddle 60%+ upside on modest loss cuts and revenue stabilization, but this ignores partner churn echoes from SVB, regulatory squeezes, and debt maturities without FCF positivity—echoing ad-tech flameouts. Downside skews 50%+ if forecasts miss, demanding tiny positions and heavy skepticism in this high-volatility trap.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.